Chemotherapy vs. Best Supportive
Care
Chemotherapy
vs. Best Supportive Care - Recent MEDLINE Abstracts
Prospective
Randomized Trial of Docetaxel Versus Best Supportive Care in Patients
with NSCLC Previously Treated with Platinum-based Chemotherapy
(Journal of Clinical Oncology)
Abstract of a Journal of Clinical Oncology article (May
2000) reporting results of a study that found treatment with docetaxel
is associated with significant prolongation of survival when compared
to best supportive care in patients with NSCLC who had previously been
treated with platinum-based chemotherapy. [5/00]
Duration of Chemotherapy
Phase
III Trial Comparing a Defined Duration of Therapy versus Continuous Therapy
Followed by Second-Line Therapy in Advanced - Stage
IIIB/IV NSCLC (PubMed Abstract)
Reports on a study published in the 3/01/02 issue of the Journal
of Clinical Oncology that compares four cycles of therapy
versus continuous therapy to determine the optimal duration of chemotherapy
in advanced NSCLC. The study showed no overall benefit in survival, response
rates, or QOL to continuing treatment with carboplatin/paclitaxel beyond
four cycles in advanced NSCLC. [3/02]
Chemotherapy
and Advanced Lung Cancer: Less Treatment May Be Enough (NCI's
cancer.gov)
Reports on a study published in the 3/01/01 issue of the Journal of
Clinical Oncology that indicates three rounds of chemotherapy
may offer the same benefit to NSCLC patients as six or more. [3/01]
Post-Surgical (Adjuvant) Chemotherapy
Some
Lung Cancer Patients Benefit from Surgery, Chemotherapy Combination (International
Adjuvant Lung Cancer Trial) and Chemotherapy
Following Surgery Improves Survival for Patients with Early Stage Lung
Cancer (People Living With Cancer)
Explains the results of two trials presented at the 2003 ASCO annual
meeting that demonstrated that patients with resected lung cancer survive
longer when treated with adjuvant chemotherapy after surgery. [6/03]
Adding
Chemotherapy to Radiation After Surgery Adds No Benefit in Lung Cancer
(NCI's cancer.gov)
Reports on a study published in the 10/26/00 issue of the New
England Journal of Medicine that found adding chemotherapy to radiation
therapy does not prolong survival in operable NSCLC. The large, randomized
study compared the chemotherapy (cisplatin and etoposide) and radiation
combination to radiation alone. Patients receiving the combined treatment
had a median survival of 38 months compared to 39 months among those receiving
radiation alone. Overall survival and recurrence rates were also similar
in the two groups. [10/00]
Platinum vs. Non-platinum Regimens?
Platinum-based
vs. Non-Platinum-based Chemotherapy in Advanced NSCLC: A Meta-Analysis
of the Published Literature (PubMed)
Describes a meta-analysis performed to compare the activity, efficacy
and toxicity of platinum-based vs. non-platinum based chemotherapy in
patients with advanced NSCLC. Concludes that response is significantly
higher with platinum-containing regimens. One-year survival was not significantly
prolonged when platinum-based therapies were compared with third-generation-based
combination regimens. Toxicity is generally higher for platinum-based
regimens. [2/05]
NSCLC: Platinum
or Nonplatinum Regimens? (Medscape)
Summary of the debate on the use of platinum vs. nonplatinum-based therapies
in NSCLC held during the 2nd International Lung Cancer Congress. Aimed
at physicians. Registration required for free access to Medscape. [8/01]
Chemotherapy Regimens:
How Many Drugs?
Benefits
of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in
Advanced NSCLC? (PubMed)
Meta-analysis published in the July 28, 2004 issue of JAMA that
examined whether adding a drug to a single-agent or to a 2-agent regimen
increased tumor response rate, survival and toxicity. Data from all randomized
controlled trials conducted from 1980 through 2001 comparing a doublet
regimen with a single-agent regimen or comparing a triplet regimen with
a doublet regimen in patients with advanced NSCLC were examined. The study
concluded that adding a second drug improved tumor response and survival
rate. Adding a third drug had a weaker effect on tumor response and no
effect on survival. [7/04]
Chemotherapy Sequence
& Response
Randomized
Phase II Study of Two Opposite Administration Sequences of Irinotecan
& Cisplatin In Patients with NSCLC
Abstract of a study published in the February 2006 issue of Cancer
that found treatment with cisplatin followed by irinotecan appears to
achieve better outcome in patients with NSCLC than does treatment with
the same drugs in the reverse order. [02/06]
|
